Library

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
the influence of Mexidol in different doses in the dynamics of the development of experimental toxic hepatitis according to indicators of hydration and free radical oxidation in the blood and liver tissue has been studied. A positive and dose-dependent effect of Mexidol on the studied physicochemical processes in the blood and liver tissue in the experiment is established, its use in patients with diffusion liver diseases is theoretically substantiated. Key words: hepatology, intoxication, free radical processes, Mexidol.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
on the model of experimentally caused intracerebral post -traumatic hematoma (hemorrhagic stroke), rats have established that the drug Mexidol is effective at a dose of 100 mg/kg (course - 7 days). The drug statistically reliably reduced the number of neurological disorders (paresis, manners), increased animal survival, improved the processes of learning and memory of rats with hemorrhagic stroke, as well as their motor activity. Key words: Mexidol, hemorrhagic stroke, neurological status, memory

Place of publication: Farmatek magazine Special Psychiatry / Neurology / 2016

Mexidol is an original domestic drug. The article describes the history of the creation of the drug, outlines modern ideas about its pharmacokinetics (including data on the penetration of Mexidol into mitochondria, as well as its effect on the activity of cytochroma-R450 isform 3A4 and protein-conveyor glycoprotein-r) and pharmacodynamics. From a biochemical point of view, the appropriateness of the use of Mexidol with hypoxia of the brain, the development of oxidative stress, with glutamate exaytotoxicity is substantiated. The comparison of Mexidol and its generics, as well as studies proving the safety of this drug, are presented.

Keywords: Mexidol, ethylmethylhydroxypirinate, pharmacokinetics, pharmacodynamics, safety

Place of publication:
a journal of neurology and psychiatry, No. 12, 2012

Summary:
Mexidol (2-El-methyl-3-gydro Xipina Ridina Succinate)-a domestic original antioxidant and anti-hyphyxant, created at the Research Institute of Pharmacology of the RAMS in the mid-80s. Mexol consists of two related and functionally significant compounds: 2-ethyl-6-methyl-3-hydroxypyridine and amber acid. The presence of 3-hydroxypyridine in the structure of Mexidol provides a complex of its antioxidant and membranotropic effects, the ability to reduce glutamate excanitotoxicity, modulate the functioning of receptors, which fundamentally distinguishes Mexol from other preparations containing amber acid. The presence of succinate in the structure of Mexidol distinguishes it from Emoxypin and other 3-oxypyridine derivatives, since the succinate is functionally significant for many processes occurring in the body and, in particular, is a substrate for increasing energy metabolism in the cell.

Place of publication:
Pharmacate, No. 6, 2009

Summary:
The article presents viewing data on pharmacological effects and pharmacokinetics of Mexidol. Neuroprotective, anti -hypic, anti -ischemic, nootropic, anti -stress, anxiolytic, anticonvulusal, anti -alcohol, anti -anatherogenic, heroesidal action of Mexidol is considered. Particular attention is paid to the effects of Mexidol in the treatment of diseases occurring with neurodegeneration, primarily acute and chronic disorders of cerebral circulation. Information is presented about the polycomponent mechanism of action of Mexidol, the important links of which are its antioxidant, membrane effects, the ability to modulate the functioning of receptors and membrane -raised enzymes, as well as restore the neurotransmitted balance.

Year of publication: 2004

Summary:
in recent years, close attention of pharmacologists and clinicians as promising drugs that effectively regulate oxidation and peroxidation processes attracted compounds of heteroamatic phenols, in particular, 3-oxypyrin derivatives. 3-oxypyridine derivatives (3-OP) belong to the simplest heterocyclic analogues of aromatic phenols and in this regard show antioxidant and anti-radical properties. They are structural analogues of the compounds of the Vitamin B6 group (pyridoxol, pyridoxal and pyridoxamine), playing an important role in the life of the body. The synthesis and analysis of the physicochemical properties of a number of original derivatives of 3-Op was carried out by L.D. Smirnov, K.M. Dyumaev, V.I. Kuzmin, and their pharmacological study was carried out in the laboratory of psychopharmacology of the Research Institute of Pharmacology of the Russian Academy of Sciences under the guidance of a honored science figure of Professor T.A. Voronina.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 6

Summary:
the state of cancellation of alcohol develops with the refusal of drinking alcohol, after prolonged or short -lived, but their massive use, is manifested by somatic symptoms and, in some cases, is complicated by the development of alcoholic seizures, alcoholic hallucinosis and alcohol delirium, which can create a threat to patients. The leading neurochemical factors underlying alcohol cancellation and its complications are the insufficient cerebral content of the GABA and the excessive activity of glutamate, which matters to therapy. First -line preparations in the treatment of alcohol and alcoholic delirium cancellation are benzodiazepines with maximum pharmacological similarities with ethanol. As an alternative to benzodiazepines and in addition to them, especially in the case of protracted delirium with therapeutic resistance, other drugs, including barbiturates, antiepileptic drugs, propofols, dexemedetomidine and antipsychoticism, can be used. Certain prospects in the treatment of alcohol cancellation syndrome are associated with ethylmethylhydroxypyridine with a succinate, which has some pharmacological similarity with benzodiazepines. Key words: alcohol disorders, alcohol cancellation syndrome, alcohol convulsions, alcoholic hallucinosis, alcoholic delirium, benzodiazepines.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 5

Summary:
A review of modern literature is presented regarding the use of Mexidol (ethylmethylhydroxypyridine succinate) in the treatment of mental (in particular, addictive) disorders. The possibility of its prescription for the correction of negative psychopathological symptoms, neurocognitive deficiency, manifestations of neuroleptic syndrome (including its extrapyramidal disorders) in the treatment of antipsychotics in patients with schizophrenic spectrum, insomnic disorders in the complex therapy of border mental disorders is shown. The possibilities of the use of the drug Mexidol in the treatment of addictive pathology, as well as the consequences of intoxication caused by alcohol and other psychoactive (in particular, narcotic) substances deserve. Key words: mental disorders, addictive pathology, Mexidol, treatment, complex therapy.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2013

Summary:
70 patients with panic disorder (PR), 30 men and 40 women were examined, whose average age was 34.5 ± 1.8 years. All patients were distinguished by the presence of dissocation disorders. Patients, depending on the characteristics of therapy, were divided into 2 groups - control and basic. Patients of the control group were treated only with an antidepressant (freedin at a dose of 150 mg per day); Mexidol (375 mg per day) was appointed to patients of the main group to antidepressant.

Place of publication:
Bulletin of experimental biology and medicine, 2012, Appendix 1

Summary:
In the treatment of patients with opium drug addiction by Mexidol and convulsan, the symptoms of withdrawal and postbustified disorders were reduced faster and to a greater extent than in the treatment according to the standard methodology. Patients used to become capable of socio-non-norment behavior, to constructive and productive actions in the treatment and rehabilitation process. Key words: Mexidol, convulsan, lamotridine, drug addiction, withdrawal disorders.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
Mexidol is an effective, economical treatment for a comprehensive treatment of convulsive syndrome of withdrawal genesis, prevents recurrence of convulsive attacks, significantly improves overall well -being and cognitive functions for a shorter period of time than other nootropic drugs. Key words: withdrawal, injury, convulsive syndrome, cognitive functions, Mexidol.

Place of publication:
Journal of Neurology and Psychiatry, 11, 2006

Summary:
the results of the clinical assessment of the effectiveness and tolerance of Mexidol are presented with its intravenous drip administration within 5-7 days in 50 cases of complicated alcohol delirium by Mexidol. The clinical condition of the patients and the dynamics of laboratory data were evaluated in comparison with the control group of patients on basic therapy without Mexidol. It was established that the use of Mexidol allows you to stop psychosis as early as possible, which in turn leads to a decrease in secondary complications and mortality. Key words: Mexidol, antioxidant, antihypoxant, alcoholic delirium, stopping.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
Mexidol was used in the treatment of various options for alcohol withdrawal syndrome. Thanks to the expressed vegetostabilizing and sedative effects of Mexidol’s therapy, it was more effective than complex traditional therapy in the removal of neurovegetative and psychopathological manifestations. Key words: alcoholism, withdrawal syndrome, Mexidol.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
the clinical effectiveness and validity of the use of Mexidol in the complex therapy of patients with post -traumatic stress disorders with typical psychopathological symptoms has been studied. The dynamics of changes in not only quantitative (experimental-psychological) indicators, but also of qualitative (clinical) features were taken into account. With the use of Mexidol, emotional lability decreased in 6% of cases, the intensity of headaches - in 36%, the level of alcoholization - in 37%, the mood background increased in 59% of cases, the level of asthenization was normalized in 82.6% of cases, the level of anxiety decreased to the norm In 70% of cases. Normalizing the processes in the central nervous system, increasing the adaptive reserves of the body, Mexol, enhances effectiveness and reduces side effects of the use of antidepressants and benzodiazepines. Thus, Mexidol is a promising drug in the treatment of post -traumatic stress disorders. Key words: post -traumatic stress disorder, Mexidol, adaptive reserves, social fences, anxiolytic activity.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
30 patients with neurotic conditions and the predominance of depressive, anxious, hysterical symptoms were examined. The effect of Mexidol was evaluated on the level of depression, anxiety, memory and attention. The positive effect of the drug is noted that contributes to social adaptation and improve the quality of life of patients. Key words: neurosis, depression, therapy, neurometabolic products, Mexidol.

Place of publication:
cardiology and cardiovascular surgery, 2023, T. 16, No. 4

Summary:
Purpose of the study. Assessment of the effect of Mexidol, as part of the complex therapy of heart failure for 10 weeks on cognitive status, quality parameters, asthenic syndrome and anxiety level in patients with XN II-III functional class (according to NYHA classification). Material and methods. An open randomized study included 60 comorbide patients with coronary heart disease (coronary heart disease) and stable chronic heart failure (COL) with cognitive disorders (KN) ≤24 points on the Montreal scale for evaluating cognitive functions (MOCA). The average age of patients was 73.4 ± 8.6 years, 53% - male, the average release fraction of 43.5 ± 10.6%. 30 patients were included in the standard therapy group with the additional purpose of Mexidol (500 mg intravenously dropped 1 time per day for 14 days, then 250 mg 3 times a day 8 weeks) and 30 patients in a standard therapy group. Initially and at the end of the study, an assessment of the effect of therapy on the cognitive status of patients on the Montreal scale of assessment of cognitive functions (Mosa), anxiety level on the Bek scale, the degree of severity and the dynamics of asthenic syndrome on the subjective scale of astheny assessment (MFI-20), and health profiles according to the questionnaire was carried out EQ-5D-5L and quality parameters based on the results of the Essence on the Minnesotsky (MlHFQ), Kansas (Kansas City CardiOMYOPATHY QUESTIONNAIRA, KCCQ) and the SF36 questionnaire “Evaluation of the quality of life”. Results. In patients who received Mexidol, in addition to standard therapy, a reliable improvement of cognitive function by 21%was revealed, a decrease in anxiety-by 38%and the severity of asthenic syndrome-by 12%, improve the overall health of the EQ-5D-5L questionnaire-by 25%by 25% , as well as the qualities of life according to the Minnesotsky questionnaire - by 48%, according to the Kansas questionnaire - by 39%. Conclusion. Mexidol, when adding to standard therapy of patients with XN II-III, functional class, reliably improves cognitive status, quality parameters, reduces the severity of asthenic syndrome and anxiety level. Key words: heart failure, cognitive status, quality of life, Mexidol.